Increasing ciprofloxacin resistance among prevalent urinary tract bacterial isolates in the Gaza Strip.
BACKGROUND
This study aims to assess common organisms causing urinary tract infection (UTI) in the Gaza Strip, Palestinian Authority and to examine the incidence of ciprofloxacin resistance in the strains of bacteria isolated from patients suspected with UTI over a six-month period.


METHODS
Ciprofloxacin was evaluated along with other commonly-used antibiotics against a total of 480 clinical isolates obtained from urine samples. The samples were collected from community patients from different parts of the Gaza Strip. Susceptibility tests were done by the Kerby Bauer method.


RESULTS
Among the tested drugs, the percent resistance rate to ciprofloxacin was 15.0 percent. However, high resistance to ciprofloxacin was detected among Acinetobacter haemolyticus (28.6 percent), Staphylococcus saprophyticus (25.0 percent), Pseudomonas aeruginosa (20.0 percent), Klebsiella pneumonia (17.6 percent) and Escherichia coli (12.0 percent). Minimal inhibitory concentration of ciprofloxacin was measured for all resistant UTI isolates.


CONCLUSIONS
This study indicates emerging ciprofloxacin resistance among most UTI bacterial pathogens. Increasing resistance against ciprofloxacin demands coordinated monitoring of its activity and rational use of the antibiotics.
Astal
Z E
ZE
Khan Younis Hospital Laboratory, Khan Younis, Gaza Strip, Palestinian Authority. zalastal@yahoo.com
D000150:Acinetobacter / Q000187:drug effects / Q000302:isolation & purification; D000293:Adolescent; D000328:Adult; D002939:Ciprofloxacin / Q000494:pharmacology* / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008877:Middle East; D010865:Pilot Projects; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification; D041162:Staphylococcus haemolyticus / Q000187:drug effects / Q000302:isolation & purification; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D002939:Ciprofloxacin